I am very impressed with VBLT and Dror seems to really just enjoy doing great science. It is amazing!
Patents
I am curious about the extent of their patents. It seems obvious that they are patenting applications of MOSPD2 targeting for monocytes and tumors using both mAbs and CAR-T modalities. I wonder if they have also considered patents surrounding companion diagnostics that include MOSPD2. If that signal is truly present on several solid tumors (Slide 33/62 & 34/62) and a significant predictor of metastasis/response/etc, then they could at least try to lock down that CDx space since they identified the target. (Roche did that with PD-L1: http://www.ventana.com/pd-l1-biomarker-assay-news)
MOSPD2 Specificity
Dror fumbles through something very important on Slide 41/62. I think what he meant to say is that MOSPD2 expression is 2-3 orders of magnitude greater on tumor cells than on monocytes? Use that knowledge to better understand the relative expression of MOSPD2 in tumors compared to all the healthy tissues shown on Slide 28/62. In short: MOSPD2 appears to be an excellent target.
My one concern is that, after tumor and monocytes, MOSPD2 expression is highest in "neural-like" cells. More on this in the next comment.
CAR-T Testing Underway
This is huge! A big challenge with CAR-T cells is finding suitable antigens. That is one reason why CAR-T therapies have been limited to targets like CD19/20 and BCMA. Clone#89 (slide 42/62) targets MOSPD2 in cancer cells but not in monocytes. If (1) they can really use Clone#89 as the basis for the antigen binding domain for CAR-T and (2) they can demonstrate tumor response in in vivo studies that evaluate several mouse tumor models (ie. BRCA, HCC), then they have hit the jackpot. He said they already have CAR Ts built, so I am very excited to track this one in the coming months.
From a science perspective, they essentially will have a process to tailor-make tissue/cell-specific CAR-Ts. From a business perspective, they will have access to several more tumor types.
However, there is one big question I have about their CAR T approach. Is MOSPD2's expression on neural cells significant enough to lead to issues? Remember, Juno canned their trials because patients kept dying of cerebral edemas. (http://www.fiercebiotech.com/biotech/juno-car-t-study-put-hold-again-after-cerebral-edemas-and-fatality-again)
Once again, thanks for the share! I am excited.
Recent VBLT News
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 07/01/2024 09:19:40 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 06/20/2024 09:01:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/10/2024 09:18:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/10/2024 09:17:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/10/2024 09:12:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/10/2024 09:07:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/10/2024 09:06:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/10/2024 09:04:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 08:30:44 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 04/19/2024 08:56:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/12/2024 12:44:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 04/11/2024 09:00:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/09/2024 09:20:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/08/2024 04:15:14 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 04/01/2024 08:30:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2024 01:00:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 01:15:22 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 02/16/2024 02:00:13 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/05/2024 10:00:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 09:05:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 04:05:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 04:05:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 04:04:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 04:04:24 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM